Interleukin-10 at the crossroads of immunity in TLR7-induced lupus - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Interleukin-10: A Key Player in Immune Regulation in TLR7-Mediated Lupus

  • By

  • Johanna Pauline Williams

  • Anaïs Amend

  • Anna-Lena Schäfer

  • Paola Fernanda Ruiz-Aparicio

  • Antoine Nicolas Kraemer

  • Aileen Qian Luo

  • Laura Riechert

  • Lara Weber

  • Baerbel Keller

  • Rudolf Armin Manz

  • Reinhard Edmund Voll

  • Nina Chevalier

  • June 22, 2026

Share

Clinical Scorecard: Interleukin-10: A Key Player in Immune Regulation in TLR7-Mediated Lupus

At a Glance

CategoryDetail
ConditionSystemic lupus erythematosus (SLE)
Key MechanismsIL-10 exhibits both pro-inflammatory and anti-inflammatory effects, influencing immune cell behavior and disease progression.
Target PopulationPatients with systemic lupus erythematosus (SLE)
Care SettingClinical research and therapeutic exploration

Key Highlights

  • IL-10 plays a dual role in SLE, promoting both inflammation and regulation.
  • Blockade of IL-10R increases IL-17 and reduces regulatory T cell frequencies.
  • IL-10 signaling primarily activates STAT3 pathways in immune cells.
  • Dysregulation of IL-10 is implicated in various autoimmune and inflammatory diseases.
  • Further research is needed to clarify IL-10's role in different disease contexts.

Guideline-Based Recommendations

Diagnosis

  • Consider IL-10 levels as potential biomarkers in SLE.

Management

  • Explore IL-10 modulation as a therapeutic target in SLE.

Monitoring & Follow-up

  • Monitor immune cell profiles and cytokine levels in SLE patients.

Risks

  • Be aware of the dual role of IL-10 which may complicate treatment strategies.

Patient & Prescribing Data

Individuals diagnosed with systemic lupus erythematosus (SLE)

IL-10's complex role necessitates careful consideration in therapeutic approaches.

Clinical Best Practices

  • Assess IL-10 signaling pathways when evaluating immune responses in SLE.
  • Tailor treatment strategies based on the inflammatory context of IL-10.

Related Resources & Content

Original Source(s)

Interleukin-10 at the crossroads of immunity in TLR7-induced lupus

  • by Johanna Pauline Williams, Anaïs Amend, Anna-Lena Schäfer, Paola Fernanda Ruiz-Aparicio, Antoine Nicolas Kraemer, Aileen Qian Luo, Laura Riechert, Lara Weber, Baerbel Keller, Rudolf Armin Manz, Reinhard Edmund Voll, Nina Chevalier

  • June 22, 2026

Related Content

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

Case Report: Overlapping multiple sclerosis and neuropsychiatric systemic lupus erythematosus with positive MOG-IgG: a case initially misdiagnosed as depression

Impact of high disease activity on damage accrual and disease outcomes in childhood-onset systemic lupus erythematosus